Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Celiac Disease - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H2 2017, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape. Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren's syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Celiac Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 10 and 6 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively. Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Celiac Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Celiac Disease - Overview Celiac Disease - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Celiac Disease - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Celiac Disease - Companies Involved in Therapeutics Development Amgen Inc Calypso Biotech SA F. Hoffmann-La Roche Ltd Glenmark Pharmaceuticals Ltd ImmusanT Inc Innovate Biopharmaceuticals Inc Intrexon Corp Selecta Biosciences Inc Takeda Pharmaceutical Company Ltd Topas Therapeutics GmbH Zedira GmbH Celiac Disease - Drug Profiles AMG-714 - Drug Profile Product Description Mechanism Of Action R&D Progress AVX-176 - Drug Profile Product Description Mechanism Of Action R&D Progress Biologic for Celiac Disease - Drug Profile Product Description Mechanism Of Action R&D Progress BNZ-2 - Drug Profile Product Description Mechanism Of Action R&D Progress CALY-002 - Drug Profile Product Description Mechanism Of Action R&D Progress ERW-1041E - Drug Profile Product Description Mechanism Of Action R&D Progress GBR-830 - Drug Profile Product Description Mechanism Of Action R&D Progress Kuma-010 - Drug Profile Product Description Mechanism Of Action R&D Progress larazotide acetate - Drug Profile Product Description Mechanism Of Action R&D Progress latiglutenase - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Tropical Spastic Paraparesis and Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Nexvax-2 - Drug Profile Product Description Mechanism Of Action R&D Progress Nexvax-3 - Drug Profile Product Description Mechanism Of Action R&D Progress Oligonucleotides for Celiac Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Protein for Celiac Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Enzymes to Inhibit Gluten for Celiac Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Peptides for Celiac Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein for Celiac Disease - Drug Profile Product Description Mechanism Of Action R&D Progress RG-7625 - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine for Celiac Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine for Celiac Disease - Drug Profile Product Description Mechanism Of Action R&D Progress vedolizumab - Drug Profile Product Description Mechanism Of Action R&D Progress ZED-1227 - Drug Profile Product Description Mechanism Of Action R&D Progress ZED-754 - Drug Profile Product Description Mechanism Of Action R&D Progress Celiac Disease - Dormant Projects Celiac Disease - Product Development Milestones Featured News & Press Releases Aug 29, 2017: ImmunogenX Announces Publication of New Latiglutenase Analyses in Digestive Disease & Science Jun 06, 2017: Innovate Biopharmaceuticals to present progress towards phase 3 celiac disease trials at BIO 2017 Convention May 12, 2017: ImmusanT Announces Publication of Positive Data from Phase 1 Trials of Nexvax2 in Celiac Disease Patients May 08, 2017: ImmusanT Reports Data on Novel Celiac Disease Diagnostic Approach May 02, 2017: ImmunogenX to Make Highlighted Presentations at DDW 2017 Feb 22, 2017: ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2 for the Treatment of Celiac Disease Feb 06, 2017: Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Celiac Disease Treatment Jan 04, 2017: Innovate Biopharmaceuticals Provides Update on larazotide acetate (INN-202) Nov 30, 2016: Zedira receives funding from the German Government for the development of transglutaminase inhibitor ZED-1227 for the treatment of diabetic nephropathy Jul 01, 2016: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug May 24, 2016: ImmusanT Reports Nexvax2 Phase 1 Data in Patients with Celiac Disease May 19, 2016: ImmusanT Announces Presentations at Digestive Disease Week 2016 May 05, 2016: Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease Mar 31, 2016: Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II Oct 20, 2015: Additional subsidy funding for clinical development of a celiac disease drug Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Celiac Disease, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Celiac Disease - Pipeline by Amgen Inc, H2 2017 Celiac Disease - Pipeline by Calypso Biotech SA, H2 2017 Celiac Disease - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 Celiac Disease - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017 Celiac Disease - Pipeline by ImmusanT Inc, H2 2017 Celiac Disease - Pipeline by Innovate Biopharmaceuticals Inc, H2 2017 Celiac Disease - Pipeline by Intrexon Corp, H2 2017 Celiac Disease - Pipeline by Selecta Biosciences Inc, H2 2017 Celiac Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017 Celiac Disease - Pipeline by Topas Therapeutics GmbH, H2 2017 Celiac Disease - Pipeline by Zedira GmbH, H2 2017 Celiac Disease - Dormant Projects, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
